Understanding angiogenic function in normal term pregnancies
Angiogenic Function at Normal Term on Placenta
Centre Hospitalier Intercommunal Creteil · NCT03981653
This study looks at how certain cells in healthy pregnancies help with blood vessel growth in the placenta to see if it can lead to better treatments for pregnancy problems like pre-eclampsia.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 750 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | Centre Hospitalier Intercommunal Creteil (other) |
| Locations | 1 site (Créteil) |
| Trial ID | NCT03981653 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the angiogenic function of trophoblasts in placentas from healthy pregnancies at term. It aims to analyze the expression of pro- and antiangiogenic factors, such as placenta growth factor (PlGF) and soluble FMS-like tyrosine kinase-1 (sFlt-1), in human differentiated trophoblastic cells. The study will also explore the effects of various chemical compounds on placental functions and trophoblastic differentiation, potentially identifying therapeutic targets for pregnancy-related pathologies like pre-eclampsia and intrauterine growth restriction. By measuring gene and protein expression variations, the research seeks to enhance understanding of placental pathophysiology.
Who should consider this trial
Good fit: Ideal candidates include women with strictly normal pregnancies or those with specific complications like gestational diabetes or pregnancy cholestasis, who are scheduled for cesarean delivery after 37 weeks.
Not a fit: Patients with multiple pregnancies, known major fetal malformations, or those experiencing pre-eclampsia or intrauterine growth restriction will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to new therapeutic strategies for managing pregnancy complications related to placental dysfunction.
How similar studies have performed: While this study explores a specific aspect of placental function, similar studies have shown promise in understanding angiogenic factors in pregnancy-related conditions.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Pregnancies with scheduled cesarean delivery \>37 weeks of amenorrhea: * strictly normal pregnancies * complicated pregnancies of gestational diabetes, insulin-treated or not * complicated pregnancies due to pregnancy cholestasis * spontaneous or in vitro fecondation (IVF) / Intracytoplasmic sperm injection (ICSI) pregnancies with or without oocyte donation Exclusion Criteria: * Patient's opposition * Age \< 18 years old * Women under the protection of justice * Multiple pregnancy * Known major fetal malformation * Pre-eclampsia and intrauterine growth retardation * Placental insertionnomaly * Type 1 diabetes * HIV-positive patient with HIV/hepatisis C virus (HCV) regardless of viral load * Patient in labour at the time of Caesarean section * Patient whose medical history results in medication being taken in pregnancy courses that may interfere with the biology of the trophoblast (immunomodulators in case of autoimmune diseases, anti-rejection drugs in case of transplant patients)
Where this trial is running
Créteil
- Centre Hospitalier Intercommunal de Créteil — Créteil, France (RECRUITING)
Study contacts
- Study coordinator: camille JUNG, MD
- Email: camille.jung@chicreteil.fr
- Phone: 00157022268
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Pregnancy Related